Loading clinical trials...
Loading clinical trials...
Afatinib in Advanced NRG1-Rearranged Malignancies: the NCT/DKTK PMO-1604 Phase-II Trial
Conditions
Interventions
Afatinib 40 MG
Locations
2
Germany
NCT Dresden
Dresden, Germany
NCT Heidelberg
Heidelberg, Germany
Start Date
July 31, 2022
Primary Completion Date
October 4, 2023
Completion Date
October 4, 2023
Last Updated
April 5, 2024
Lead Sponsor
German Cancer Research Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions